Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. (26th December 2018)

• Record Type: Journal Article
• Authors: Ciardi, Maria R; Iannetta, Marco; Zingaropoli, Maria A; Salpini, Romina; Aragri, Marianna; Annecca, Rosanna; Pontecorvo, Simona; Altieri, Marta; Russo, Gianluca; Svicher, Valentina; Mastroianni, Claudio M; Vullo, Vincenzo
• Is Part Of: Open forum infectious diseases. Volume 6:Number 1(2019)
• Publication Date: 2018-12-26
• Subjects: HBV -- CD20 -- liver -- biologics -- entecavir -- prophylaxis; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofy356
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ocrelizumab. HBV reactivation was monitored with HBV-DNA and HBV surface antigen periodic assessment. Anti-HBV treatment with entecavir was started after HBV-DNA detection. Ocrelizumab can reactivate viral replication in patients with resolved HBV infection. HBV reactivation monitoring seems an effective and safe option for the management of these patients. More studies are needed to assess the optimal management of HBV reactivation in MS patients on ocrelizumab treatment.